Compugen saw the highest growth of 0.59% in patent filings and no patents were granted in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.59% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Compugen’s patent filings and grants. Buy the databook here.
Compugen has been focused on protecting inventions in Australia(AU) with two publications in Q2 2024
The Australia(AU) Patent Office dominates the patent filings and grants with nearly 33% filings and 100% grants. The Australia(AU), European Patent Office(EPO), and United States(US) patent Office are among the top ten patent offices where Compugen is filings its patents. Among the top granted patent authorities, Compugen has 100% of its grants in Australia(AU).
Roche and Johnson & Johnson could be the strongest competitors for Compugen
Patents related to climate change and rare diseases lead Compugen's portfolio
Compugen has the highest number of patents in climate change followed by, rare diseases. For climate change, nearly 67% of patents were filed and no patents were granted in Q2 2024.
Poliomyelitis related patents lead Compugen portfolio
Compugen has highest number of patents in poliomyelitis.
For comprehensive analysis of Compugen's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.